ALVOW

Alvotech is a biotech company specializing in the development and manufacture of biosimilar medicines for global markets. Headquartered in Reykjavik, Iceland, with manufacturing facilities in Iceland and planned operations in other locations, the company focuses on creating high-quality, cost-effective alternatives to biologic therapies. Alvotech's portfolio targets multiple therapeutic areas including autoimmune disorders, eye disorders, and oncology, with several biosimilar candidates at various stages of development and commercialization. The company operates through strategic partnerships with pharmaceutical companies worldwide to commercialize its biosimilar products across different regions. Alvotech's business model centers on developing biosimilars from concept through manufacturing, then licensing them to partners for distribution. Key product candidates include biosimilars referencing blockbuster biologics such as Stelara, Eylea, and Prolia. In 2022, Alvotech completed its business combination with Oaktree Acquisition Corp. II and began trading on NASDAQ. The company employs over 800 people and operates a vertically integrated development and manufacturing platform. Recent milestones include regulatory approvals and submissions in multiple markets, including Europe and the United States. Alvotech has established commercialization partnerships with major pharmaceutical companies including Teva Pharmaceuticals and Alvogen, positioning itself as an emerging player in the global biosimilars market as healthcare systems increasingly seek affordable alternatives to expensive biologic medications.